Soligenix

Soligenix Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Soligenix (SNGX) as of Oct 16, 2026 is -2,042.22. In the previous year, Cash Conversion Cycle (CCC) was -472.10 — a change of 332.58% (lower).

Cash Conversion Cycle

-2,042.22

YoY

332.58%

Last updated:

Cash Conversion Cycle (CCC) of Soligenix is 2024 -2,042.22 . Cash Conversion Cycle (CCC) of Soligenix was 2023 -472.10 . It decreases by 332.58% lower compared to the previous year.

The Soligenix Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2017
-86.02 USD
Jan 1, 2018
-85.21 USD
Jan 1, 2019
-164.10 USD
Jan 1, 2020
-389.10 USD
Jan 1, 2021
66.69 USD
Jan 1, 2022
-2,386.45 USD
Jan 1, 2023
-472.10 USD
Jan 1, 2024
-2,042.22 USD
The Soligenix Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-2,042.22+332.58%
-472.10-80.22%
-2,386.45-3,678.66%
66.69-117.14%
-389.10+137.12%
-164.10+92.58%
-85.21-0.94%
-86.02+171.74%
-31.65-54.35%
-69.34-58.07%
-165.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Cash Conversion Cycle (CCC) of Soligenix is -2,042.22 in 2024.

Cash Conversion Cycle (CCC) of Soligenix changed from -472.10 to -2,042.22, representing a 332.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Soligenix since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Soligenix with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Soligenix

All Key Metrics — Soligenix